Company to focus on pipeline of Pentarins™ as a unique and promising approach to treating solid tumor cancers Lead drug candidate PEN-221 targeting neuroendocrine and small cell lung cancers to advance into clinical studies in 2016   WATERTOWN, Mass.–(BUSINESS WIRE)–Tarveda Therapeutics, Inc., formerly Blend Therapeutics, today announced that it has secured $38 million in Series […]